# Fibraxis ## Posts - [The Role of the CXCL12-CXCR4 Pathway in COPD](https://fibraxis.com/cxcl12-cxcr4-pathway-copd/): Our CEO Dr Bignold, and our CSO Dr Johnson, recently published an invited editorial on the role of the CXCL12-CXCR4 pathway in chronic obstructive pulmonary disease (COPD) in the American Journal of Respiratory Cell and Molecular Biology. Read more here:  https://www.atsjournals.org/doi/10.1165/rcmb.2025-0235ED - [CEO chosen for an ATS ECP Highlight](https://fibraxis.com/ceo-ats-ecp-highlight/): CEO’s work has been highlighted by the American Thoracic Society Recently, our CEO Dr. Bignold, has been highlighted by the American Thoracic Society as one of the exciting Early Career Professionals in the field of Respiratory Structure and Function. As part of the ECP working group for this area of lung research, she has made invaluable […] - [Chemokine CXCL12 drives pericyte accumulation and airway remodeling in allergic airway disease](https://fibraxis.com/cxcl12-pericyte-airway-disease/): The foundational research supporting Fibraxis, this paper demonstrates the role of CXCL12 in airway remodelling and the impact of neutralising this pathway, improving lung function by modulating lung structure. Read more here: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-022-02108-4 ## Pages - [Contact](https://fibraxis.com/contact-us/): Get in Touch with Fibraxis Are you an investor who wants more information or a patient who wants to be involved in our patient advisory group? Feel free to reach out to our team using the form below, we’d love to hear from you! Get in touch Contact Form Contact Details Fibraxis Ltd Aston University […] - [Our Team](https://fibraxis.com/our-team/): Meet the team driving Fibraxis Forward Our leadership combines decades of expertise in lung biology, drug discovery, and translational research to deliver a breakthrough in asthma care. Explore Our Team Chief Executive Officer Dr Rebecca Bignold, PhD Rebecca has a prolific research career regarding allergic asthma, in particular, the contribution of pericytes (a type of […] - [Fibraxis Background](https://fibraxis.com/background/): From breakthrough discovery to real-world impact Born from pioneering research at Aston University, Fibraxis is transforming asthma care with a revolutionary new therapy. View the technology Our Path to Innovation Fibraxis Background Fibraxis is a pioneering spin-out company originating from extensive research conducted in Dr. Jill Johnson’s laboratory at Aston University, Birmingham. As dedicated biomedical […] - [Potential Impact](https://fibraxis.com/potential-impact/): Real world potential impact for patients Our drug has the potential to impact the lives of all asthma sufferers. As a low-cost, easy-to-use medication with the capacity to reduce exacerbations and improve quality of life, we hope to bring a future where breathing freely is no longer a struggle. Learn more Designed for Everyday Use […] - [Our Drug](https://fibraxis.com/our-drug/): A First-in-Class Asthma therapeutic We’ve created the first asthma therapeutic that targets detrimental changes to lung structure, not just the immune system. A breakthrough treatment designed to repair, restore, and redefine how asthma is managed. Learn more Redefining How Asthma Is Treated Breaking New Ground in Asthma Treatment We have developed the first asthma therapeutic […] - [The Science](https://fibraxis.com/the-science/): The Science behind our Asthma Therapy Our technology is based on years of research into the lung structure and function. Below we will outline a few key aspects of the lung structure in asthma that our drug aims to target. Learn more Why Lung Structure Matters in Asthma Lung Structure Asthma is a disease of […] - [Technology](https://fibraxis.com/technology/): The Technology behind Fibraxis Using our combined 30 years’ experience in lung research, we have developed a revolutionary new way to treat asthma. Below we outline the science underpinning our new therapeutic, information about the drug, and the impact it could have on asthma patients everywhere. View the technology The technology Redefining Asthma Treatment Harnessing […] - [Home](https://fibraxis.com/): Targeting Fibrosis by inhibiting Chemotaxis A new revolution in asthma care is on its way. Fibraxis are developing a first-in-class inhalable daily medication that halts and reverses the structural lung damage that occurs in asthma. View the technology Get in touch Revolutionising Asthma Care for a Healthier Tomorrow Our innovative inhaled medication not only alleviates […] - [Privacy Policy](https://fibraxis.com/privacy-policy/): Privacy Policy At Fibraxis, accessible from https://www.Fibraxis.com/, one of our main priorities is the privacy of our visitors. This Privacy Policy document contains types of information that is collected and recorded by Fibraxis and how we use it. If you have additional questions or require more information about our Privacy Policy, do not hesitate to contact […] ## Optional - [Agent (MCP protocol)](websites-agents.hostinger.com/fibraxis.com/mcp) [comment]: # (Generated by Hostinger Tools Plugin)